FDA expands ANKTIVA BCG label to cover papillary NMIBC.

ImmunityBio announced an FDA expansion of the ANKTIVA plus BCG indication to include patients with BCG-unresponsive cystitis or papillary-only tumors. Market relevance: Expands commercial potential to an additional 85% of the target patient population.